- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001866661/sample
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under
development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising
pipeline
- In-depth analysis of the product's current stage of development, territory and estimated
launch date
Companies Mentioned:
Acorda Therapeutics Inc
Adamis Pharmaceuticals Corp
Advent Pharmaceuticals Pty Ltd
Aespira Ltd.
AKELA Pharma Inc.
Bayer HealthCare AG
Bespak Europe Ltd
Boehringer Ingelheim GmbH
Circassia Pharmaceuticals Plc
GlaxoSmithKline Plc
MannKind Corp
Monash University
Nanotherapeutics Inc
Nektar Therapeutics
Novartis AG
OPKO Health Inc
Pharmaxis Ltd
Respira Therapeutics Inc
Sandoz International GmbH
Sheffield Hallam University